Sensus Healthcare (NASDAQ:SRTS) Issues Earnings Results, Misses Expectations By $0.04 EPS

Sensus Healthcare (NASDAQ:SRTS) announced its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Here are the key takeaways from Sensus Healthcare’s conference call:

• Sensus says new dedicated CPT codes effective Jan 1, 2026 materially improve reimbursement — including about a 300% increase in the per?fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.
• Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company’s historically largest customer; adjusted EBITDA was negative $4.2 million and net loss was $2.6 million, though management notes underlying growth when excluding that customer.
• Management is prioritizing recurring revenue through the Sensus Link software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.
• Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~70% purchases of systems in the quarter, the launch of Sensus Healthcare Financial Services, and a stronger conference-driven pipeline — underpin management’s expectation of higher Q2/H2 revenue and a path to full?year profitability.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS traded down $1.03 during midday trading on Friday, reaching $3.08. 665,134 shares of the stock were exchanged, compared to its average volume of 84,977. Sensus Healthcare has a 12 month low of $2.82 and a 12 month high of $5.92. The company has a market capitalization of $50.70 million, a price-to-earnings ratio of -6.55 and a beta of 1.19. The business has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $4.16.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after acquiring an additional 3,766 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the fourth quarter worth about $513,000. Rothschild Wealth LLC acquired a new stake in shares of Sensus Healthcare during the fourth quarter worth about $500,000. State Street Corp raised its position in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares during the period. Finally, Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the 4th quarter valued at about $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Maxim Group reduced their price objective on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday. Finally, Alliance Global Partners initiated coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 target price for the company. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $6.88.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.